William L Redmond

24PUBLICATIONS
43CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tissue engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.

Ryan J Sullivan, Anthony R Cillo, Robert L Ferris

|May 22, 2025
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.

|Apr 09, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill

|Jan 15, 2025
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.

Kengo Tanigawa, William L Redmond

|Jun 21, 2023
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.

David B Page, Joanna Pucilowska, Brie Chun

|May 01, 2023
Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel.

Daniel C Rose, Annah S Rolig, William L Redmond

Pageof 4

Frequent Collaborators

9 joint publications

Annah S Rolig

3 joint publications

Yoshinobu Koguchi

2 joint publications

Venkatesh Rajamanickam

2 joint publications

Brendan D Curti